Terms: = Colorectal cancer AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1 AND Prognosis
746 results:
1. Genomic Alterations and Clinical Characterization in Chinese Patients with Metastatic colorectal cancer.
Zhang XH; Zhou JQ; Wei Q; Li J; Xu T; Bai CM; Zhou JF; Wang XC
Discov Med; 2024 Jul; 36(186):1477-1485. PubMed ID: 39054718
[TBL] [Abstract] [Full Text] [Related]
2. Role of blood metabolites in mediating the effect of gut microbiome on the mutated-RAS/braf metastatic colorectal cancer-specific survival.
Xiang Y; Zhang C; Wang J; Cheng Y; Wang K; Wang L; Tong Y; Yan D
Int J Colorectal Dis; 2024 Jul; 39(1):116. PubMed ID: 39046546
[TBL] [Abstract] [Full Text] [Related]
3. Novel drug resistance mechanisms and drug targets in braf-mutated peritoneal metastasis from colorectal cancer.
Lund-Andersen C; Torgunrud A; Kanduri C; Dagenborg VJ; Frøysnes IS; Larsen MM; Davidson B; Larsen SG; Flatmark K
J Transl Med; 2024 Jul; 22(1):646. PubMed ID: 38982444
[TBL] [Abstract] [Full Text] [Related]
4. [Clinicopathological features and prognosis of sporadic mismatch repair deficient colorectal cancer].
Wang H; Hong RP; Chen JC; Wang J; Zhang ZJ; Ren XY; Wu HW; Liang ZY
Zhonghua Bing Li Xue Za Zhi; 2024 Jul; 53(7):702-708. PubMed ID: 38955702
[No Abstract] [Full Text] [Related]
5. Progress in clinical diagnosis and treatment of colorectal cancer with rare genetic variants.
Chen S; Gu J; Wu K; Zhao X; Lu Y
Cancer Biol Med; 2024 Jun; 21(6):473-83. PubMed ID: 38940668
[TBL] [Abstract] [Full Text] [Related]
6. [Incidence of common gene mutations in early-onset colorectal cancer and the association with cancer survival: a meta-analysis].
Zhang RQ; Li SH; Hu TJ; Xu LY; Zhu YS; Li X
Zhonghua Wei Chang Wai Ke Za Zhi; 2024 May; 27(5):495-506. PubMed ID: 38778689
[TBL] [Abstract] [Full Text] [Related]
7. The Relationship of Microsatellite Instability with braf and p53 Mutations and Histopathological Parameters in colorectal Adenocarcinoma.
Gündoğar Ö; Bektaş S; Yıldırım E; Gönüllü D
Ann Ital Chir; 2024; 95(2):181-191. PubMed ID: 38684491
[TBL] [Abstract] [Full Text] [Related]
8. braf mutations and survival with surgery for colorectal liver metastases: A systematic review and meta-analysis.
Petrelli F; Arru M; Colombo S; Cavallone M; Cribiu' FM; Villardita V; Floris P; Digiesi L; Severgnini G; Moraes MT; Conti B; Celotti A; Viti M; Sozzi A
Eur J Surg Oncol; 2024 Jun; 50(6):108306. PubMed ID: 38603866
[TBL] [Abstract] [Full Text] [Related]
9. [colorectal adenocarcinoma with enteroblastic differentiation: a clinicopathological analysis of eight cases].
Wang Q; Zhang Y; Tan C; Ni SJ; Huang D; Chang B; Sheng WQ; Wang L
Zhonghua Bing Li Xue Za Zhi; 2024 Apr; 53(4):370-376. PubMed ID: 38556821
[No Abstract] [Full Text] [Related]
10. Concomitant expression patterns of CDX2 and SATB2 as prognostic factors in stage III colorectal cancers.
Lee JA; Park HE; Jin HY; Jin L; Cho NY; Bae JM; Kim JH; Kang GH
Ann Diagn Pathol; 2024 Aug; 71():152289. PubMed ID: 38555678
[TBL] [Abstract] [Full Text] [Related]
11. Dynamic ctDNA-based analysis of drug-resistant gene alterations at RAS/braf wild-type metastatic colorectal cancer patients after cetuximab plus chemotherapy as the first-line treatment.
Zhou YW; Zhao X; Ni L; Cao P; Leng WB; Zhu Q; Gou HF; Zhang J; Li XF; Qiu M
Int Immunopharmacol; 2024 Apr; 131():111887. PubMed ID: 38503018
[TBL] [Abstract] [Full Text] [Related]
12. BCL-X
Jenkins LJ; Luk IY; Chionh F; Tan T; Needham K; Ayton J; Reehorst CM; Vukelic N; Sieber OM; Mouradov D; Gibbs P; Williams DS; Tebbutt NC; Desai J; Hollande F; Dhillon AS; Lee EF; Merino D; Fairlie WD; Mariadason JM
Cell Death Dis; 2024 Mar; 15(3):183. PubMed ID: 38429301
[TBL] [Abstract] [Full Text] [Related]
13. colorectal neuroendocrine carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasm: Prognostic factors and PD-L1 expression.
Ho YH; Hsu CY; Yau Li AF; Liang WY
Hum Pathol; 2024 Mar; 145():80-85. PubMed ID: 38423221
[TBL] [Abstract] [Full Text] [Related]
14. Clinical and genetic factors associated with tumor response to neoadjuvant (chemo)radiotherapy, survival and recurrence risk in rectal cancer.
Hammarström K; Nunes L; Mathot L; Mezheyeuski A; Lundin E; Korsavidou Hult N; Imam I; Osterlund E; Sjöblom T; Glimelius B
Int J Cancer; 2024 Jul; 155(1):40-53. PubMed ID: 38376070
[TBL] [Abstract] [Full Text] [Related]
15. Integrating cfDNA liquid biopsy and organoid-based drug screening reveals PI3K signaling as a promising therapeutic target in colorectal cancer.
Yang H; Xiao X; Zeng L; Zeng H; Zheng Y; Wang J; Li G; Dai W; He Y; Wang S; Peng J; Chen W
J Transl Med; 2024 Feb; 22(1):132. PubMed ID: 38310289
[TBL] [Abstract] [Full Text] [Related]
16. Assessing the Therapeutic Impacts of HAMLET and FOLFOX on braf-Mutated colorectal cancer: A Study of cancer Cell Survival and Mitochondrial Dynamics In Vitro and Ex Vivo.
Žilinskas J; Stukas D; Jasukaitienė A; Žievytė I; Balion Z; Šapauskienė J; Banienė R; Paužas H; Lizdenis P; Čėsna V; Dambrauskas Ž; Gulbinas A; Tamelis A
Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256402
[No Abstract] [Full Text] [Related]
17. Genetic Polymorphisms and Tumoral Mutational Profiles over Survival in Advanced colorectal cancer Patients: An Exploratory Study.
Cayún JP; Cerpa LC; Colombo A; Cáceres DD; Leal JL; Reyes F; Gutiérrez-Cáceres C; Calfunao S; Varela NM; Quiñones LA
Curr Oncol; 2024 Jan; 31(1):274-295. PubMed ID: 38248103
[TBL] [Abstract] [Full Text] [Related]
18. The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review.
Ciardiello D; Mauri G; Sartore-Bianchi A; Siena S; Zampino MG; Fazio N; Cervantes A
Cancer Treat Rev; 2024 Mar; 124():102683. PubMed ID: 38237253
[TBL] [Abstract] [Full Text] [Related]
19. colorectal Carcinoma With Sarcomatoid Components: Report of 15 Cases and Literature Review of an Exceedingly Rare Carcinoma Subtype.
Golconda U; McHugh KE; Allende DS; Collins K; Henn P; Lacambra M; Bejarano PA; Groisman GM; Loughrey MB; Monappa V; Zhang X; Hornick JL; Gonzalez RS
Am J Surg Pathol; 2024 Apr; 48(4):465-474. PubMed ID: 38155543
[TBL] [Abstract] [Full Text] [Related]
20. Targeted Mass Spectrometry Analyses of Somatic Mutations in colorectal cancer Specimens Using Differential Ion Mobility.
Wu Z; Bonneil É; Belford M; Boeser C; Dunyach JJ; Thibault P
J Proteome Res; 2024 Feb; 23(2):644-652. PubMed ID: 38153093
[TBL] [Abstract] [Full Text] [Related]
[Next]